The traditional model of chemistry analyzer distribution has failed emerging healthcare systems. Premium manufacturers design for ideal laboratory conditions found in Western hospitals - pristine DI water, perfect temperature control, enormous budgets - then attempt to retrofit these solutions for developing regions.
The evidence of this failure sits in laboratories across Kenya, Mexico, Guatemala, and Eastern Europe. Old, refurbished Beckman analyzers that were inappropriate when new and are worse after years of service. Equipment purchased because it was affordable but never designed for the infrastructure challenges of emerging markets.
Meanwhile, basic chemistry testing - glucose, creatinine, liver enzymes - remains out of reach for millions of patients whose treatment depends on these results.
A better way recognizes chemistry analyzers must work with the infrastructure that exists, not the infrastructure manufacturers wish existed.
HTI chemistry analyzers can use tap water instead of demanding expensive DI water systems. They maintain accuracy when conditions aren’t ideal. They're supported by regional teams who understand that when an analyzer fails, it's not just equipment downtime - it's diabetic patients without monitoring, kidney disease going undetected, and cardiac cases missing critical biomarkers.